Lipocine (NASDAQ:LPCN) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) [Yahoo! Finance]
Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine (NASDAQ:LPCN) had its price target lowered by analysts at HC Wainwright from $8.00 to $7.00. They now have a "buy" rating on the stock.
Lipocine (NASDAQ:LPCN) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.